BNTX BioNTech Pharma: Forward P/S Multiple
BioNTech SE is optimizing vaccine production and delivery by leveraging external manufacturing capacities and outsourced testing. Its proprietary mRNA platform and exclusive alliances with industry behemoths create powerful scientific synergy. A shift in the forward P/S, where the parameter has settled at 7.50, helps assess market expectations amid the reallocation of capital toward the development of innovative cancer treatments.
BioNTech Pharma - analytical breakdowns and key metrics (BNTX)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- business debt structure and liquidity details:
- financial results and valuation multiples details:
BNTX - Final Profit|Future Profit BioNTech SE|BNTX - Company Value to Net Income|Future Price to Earnings BioNTech Group|BNTX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple BioNTech Pharma|BNTX - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) BioNTech|BNTX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months biontech.de|BNTX - Earnings per share growth this year|Expected earnings per share growth for next year BioNTech SE
- sales volume and revenue indicators:
General company analysis:BioNTech BNTX
A conservative approach to analyzing BioNTech SE requires comparing market capitalization with expected revenue. This ratio measures the cost per unit of future sales, reflecting market expectations regarding the monetization of mRNA patents and oncology developments. By analyzing the projected P/S multiple, an investor can assess the degree of asset overvaluation amid strict FDA and EMA regulatory oversight, thereby determining the company's investment profile.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|Abivax Pharma (ABVX) - Market Cap to Future Revenue Ratio|ADMA Bio - Forward P/S Multiple|PTGX: Price-to-Projected Revenue Ratio|IMVT: Forward P/S Multiple|KNSA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Grifols|Market Cap to Future Revenue Ratio Adaptive Biotech ADPT|Price-to-Projected Revenue Ratio Celldex (CLDX)|Aurinia Corp - Market Cap to Projected Revenue|BioCryst - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio VERA (veratx.com)|Dianthus Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pharvaris NV|ABCL: Forward P/S Multiple|Forward Price-to-Revenue Multiple Tourmaline|PGEN (Precigen, Inc.) - Forward P/S Multiple|PHAR: Forward Price to Sales|Forward Price-to-Revenue Multiple NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Cap to Expected Sales Ratio Immunome Bio (IMNM)|Gossamer Bio, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio kalvista.com|SEPN: Forward P/S Multiple|PVLA (Pieris Pharma) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Savara Corp|Market Cap to Projected Revenue RIGL (Rigel Corp)|Forward Price-to-Revenue Multiple ANAB (AnaptysBio, Inc.)|Price to Expected Revenue Ratio ATXS|enGene - Forward Price-to-Revenue Multiple|RAPT: Market Cap to Projected Revenue|JBIO - Price-to-Projected Revenue Ratio|Future Price to Revenue ACRS|KYTX: Forward P/S Multiple|tizianalifesciences.com - Forward Price to Sales|CABA (Cabaletta Bio) - Forward P/S Multiple|Forward P/S Multiple Ventyx Biosciences Inc.|Price-to-Projected Revenue Ratio Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN - Forward Price-to-Revenue Multiple|Climb Bio - Forward P/S Multiple|ZURA - Forward P/S Multiple|ATYR (aTyr) - Forward Price-to-Revenue Multiple|Adagene Inc. - Forward Price to Sales|IMA (ImageneBio) - Forward P/S Multiple|Shattuck Therapeutics (STTK) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|Forward Price-to-Revenue Multiple connectbiopharm.com CNTB|Price-to-Projected Revenue Ratio Immunic IMUX|ATRA - Forward Price-to-Revenue Multiple|IFRX: Forward Price-to-Revenue Multiple|XFOR - Forward P/S Multiple|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CELU|INMB (INmune Bio Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Barinthus Biotherapeutics Corp BRNS|Forward P/S Multiple KZR|Price-to-Projected Revenue Ratio SABS (sabbiotherapeutics.com)|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Market Cap to Expected Sales Ratio Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio GeoVax Corp|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue IBIO|Forward Price-to-Revenue Multiple CARM|XTLB (XTL Biopharmaceuticals Ltd) - Price to Expected Revenue Ratio|Forward P/S Multiple BOLT|HCWB - Market Cap to Future Revenue Ratio|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM - Forward Price-to-Revenue Multiple|Aditxt Corp - Forward P/S Multiple|Forward Price to Sales GRI (GRI Bio Inc)|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics - Forward Price to Sales|Price-to-Projected Revenue Ratio Revelation Biosciences|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Forward P/S Multiple SCNI|CALI - Market Cap to Future Revenue Ratio|Forward P/S Multiple AFMD (Affimed N.V.)|Allakos Inc - Price-to-Projected Revenue Ratio|HOOK - Price-to-Projected Revenue Ratio|IGMS (IGM Biosciences, Inc.) - Market Cap to Projected Revenue|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|OCEA: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple TCBP|Market Cap to Projected Revenue THRD (Third Harmonic Bio Inc)
